Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVd versus VPd in newly diagnosed multiple myeloma with renal insufficiency
ChiCTR2400086035Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of daratumumab, bortezomib, dexamethasone and pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Renal response rate and Bone marrow MRD negative rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
daratumumabbortezomibdexamethasonepomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400086035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086035.